Latus Bio
Signal active
Organization
Contact Information
Overview
Latus Bio focuses on developing innovative gene therapy candidates using precision delivery to enhance the lives of patients. Latus identified proprietary AAV capsids for clinical use. The company plans to administer low doses of its product candidates, aiming to improve clinical safety and manufacturing.
About
Industries
Biotechnology, Biopharma, Genetics
Founded
2022
Employees
11-50
Headquarters locations
N/A
Social
Funding Rounds
Funding rounds
1
Investors
7
Lead Investors
0
Total Funding Amount
$54.0M
Details
1
Latus Bio has raised a total of $54.0M in funding over 1 rounds.
| Announcement date | Transaction name | Number of Investors | Money raised | Lead Investor |
|---|---|---|---|---|
| 2024 | Early Stage Venture | 54.0M |
Investors
Latus Bio is funded by 11 investors.
| Investor Name | Lead Investor | Funding Round | Partners |
|---|---|---|---|
| Modi Ventures | - | FUNDING ROUND - Modi Ventures | 54.0M |
| The Children's Hospital of Philadelphia | - | FUNDING ROUND - The Children's Hospital of Philadelphia | 54.0M |
| Latus Bio | - | FUNDING ROUND - Latus Bio | 54.0M |
| Ben Franklin Technology Partners | - | FUNDING ROUND - Ben Franklin Technology Partners | 54.0M |
Recent Activity
News
May 09, 2024
Pulse 2.0 - Latus Bio: Patient-Centric And Product-Oriented Gene Therapy Company Raises $54 Million
News
May 09, 2024
Technical.ly - Philly daily roundup: Tech walks; Join us at Builders; Latus Bio raises $54M
News
May 03, 2024
BioWorld MedTech - Backed by $54M, biotech veterans, Latus targets new gene therapies
News
May 03, 2024
FinSMEs - Latus Bio Raises $54M in Series A Financing
News
May 03, 2024
KED Global - Samsung Life Science invests in US biotech firm Latus Bio
News
May 03, 2024
Korea JoongAng Daily - Samsung's Life Science Fund invests in Seattle's Latus Bio